

³¹**Abstract**

³²**Background and objectives.** SARS-CoV-2 infection causes a spectrum of clinical disease 33 presentation, ranging from asymptomatic to fatal. While neutralising antibody (NAb) responses 34 correlate with protection against symptomatic and severe infection, the contribution of the T cell ³⁵response to the resolution or progression of disease is still unclear. Optimal protective immunity 36 may require activation of distinct immune pathways. As such, defining the contribution of 37 individual T cell subsets to disease outcome is imperative to inform the development of next-38 generation COVID-19 vaccines. To address this, we performed immunophenotyping of T cell 39 responses in unvaccinated individuals, representing the full spectrum of COVID-19 clinical ⁴⁰presentation. **Methods.** Spectral cytometry was performed on peripheral blood mononuclear cell 41 samples from patients with PCR-confirmed SARS-CoV-2 infection. Computational and manual ⁴²analyses were used to identify T cell populations associated with distinct disease states through ⁴³unbiased clustering, principal component analysis and discriminant analysis. **Results.** Critical 44 SARS-CoV-2 infection was characterised by an increase in activated and cytotoxic $CD4^+$ (CTL) 45 cells of a T follicular helper (T_{FH}) or effector memory re-expressing CD45RA (T_{EMRA}) phenotype. 46 These $CD4^+$ CTLs were largely absent in those with less severe disease. In contrast, those with ⁴⁷asymptomatic or mild disease were associated with high proportions of naïve T cells and reduced 48 expression of activation markers. **Conclusion.** Highly activated and cytotoxic $CD4^+$ T cell 49 responses may contribute to cell-mediated host tissue damage and progression of COVID-19. 50 Potential for induction of these detrimental T cell responses should be considered when developing 51 and implementing effective COVID-19 control strategies.

52

⁵³**Keywords.** SARS-CoV-2, COVID-19, T cells, Spectral Cytometry, CD4-CTLs.

⁵⁴**Introduction**

55 The Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has been ongoing 56 since March of 2020. As of February 2023, over 754 million cases of SARS-CoV-2 infection and 57 6.83 million fatalities from coronavirus disease 2019 (COVID-19) have been reported.¹ While 58 several vaccines are now available for use, SARS-CoV-2 remains a leading cause of infectious 59 disease death globally. One of the major challenges with SARS-CoV-2 infection is the spectrum of ⁶⁰COVID-19 clinical presentation, ranging from asymptomatic to fatal. It is thought that more severe 61 disease results from a dysregulated immune response to infection; however, variability in this ⁶²immune dysfunction between individuals has limited understanding of the correlates of disease ⁶³severity. Developing a more comprehensive understanding of the immune response across the ⁶⁴spectrum of COVID-19 clinical presentation will help to differentiate protective from pathogenic ⁶⁵immune responses. This is essential to inform the development of next-generation therapies and ⁶⁶vaccines against SARS-CoV-2, with improved longevity and efficacy against newly emerging 67 variants of concern (VOC).

⁶⁸The key correlate of protective immunity against infection and severe disease in COVID-19 is 69 neutralising antibody responses (NAb) ^{2,3}As such, the factors that contribute to breakthrough 70 infection following vaccination centre around humoral immune responses, such as waning NAb 71 titres, and antibody escape mutations on globally dominant VOC.^{$4-9$} The T cell response appears to 72 have greater longevity than detectable NAbs, with sustained response to antigen stimulation 73 demonstrated >1-year post-infection.^{10,11} Additionally, the dominant T cell epitopes do not overlap 74 with areas of high mutation on variant viruses, and as a result the T cell response is preserved 75 against antibody-escape VOC. $9,12-16$ Considering the limitations of current vaccines, it has been 76 suggested that the long-lived T cell response against SARS-CoV-2 variants may contribute to 77 protective immunity in the absence of a robust humoral immune response.^{12,13,16} While NAb 78 responses have been shown to tightly correlate with protection against disease, no such correlation

79 has been shown with the T cell response to $SARS-CoV-2$ ¹⁷. There is evidence that polyfunctional 80 and cross-reactive T cell responses to seasonal coronaviruses are associated with milder disease and 81 faster viral clearance.^{18–20} However, several studies have also described an expansion of highly 82 activated T cells in severe COVID-19, that could potentially contribute to excessive inflammatory 83 immune responses and host-tissue damage.^{21–23} As such, whether T cells play a protective or 84 pathogenic role in COVID-19 is still unresolved.

85

86 To better define the role of T cell subsets, we performed an explorative investigation into T cell 87 phenotypes across the clinical spectrum of COVID-19 presentation, utilising an unbiased analysis 88 approach with a T-cell-centric high-dimensional cytometry panel. We report that critical COVID-89 19 infection is characterised by a shift from naïve T cell phenotypes to an expansion of cytotoxic 90 $CD4+T$ lymphocyte subsets.

⁹¹**Results**

⁹²**The T cell compartment distinguishes critical SARS-CoV-2 infection from other disease** ⁹³**states.**

⁹⁴To obtain a global view of the T cell response within and between disease states, peripheral blood 95 mononuclear cells (PBMCs) were isolated from the blood of patients and spectral cytometry was 96 performed using a T cell-centric antibody panel. Initially, T cell populations were manually gated ⁹⁷(Figure s1) and differences in the proportion of each population between patients were identified by 98 an unsupervised Principal Component Analysis (PCA), where each data point represents one patient 99 sample (Figure 1a). When the COVID-19 severity of each patient was superimposed onto the PCA 100 patients with critical infection separated distinctly across the first component (dim 1, accounted for ¹⁰¹31.8% of the variance) from most other patient samples (Figure 1a). Visualisation of the 102 contribution of each T cell population proportion to the principal components revealed that the 103 expression of activation/proliferation markers HLA-DR, Granzyme B (GZMB), Perforin (PFN), 104 and Ki-67 on central memory (T_{CM}), effector memory (T_{EM}), and effector memory re-expressing 105 CD45RA (T_{EMRA}) contribute to the separation of samples in dimension 1 (Figure 1b). Furthermore, 106 the proportions of these activated, memory $CD4^+$ and $CD8^+$ T cell subsets were negatively 107 correlated to those of $CD4^+$ and $CD8^+$ naïve T cells (T_N) (Figure 1b).

109 Metaclusters of cytotoxic CD4⁺ T cells differentiate critical and severe SARS-CoV-2 infection

110 To determine which T cell populations may be implicated in progression from severe to critical ¹¹¹COVID-19, patients in those groups were selected for further analysis. To fully capture the 112 heterogeneity of activation and cytotoxic marker expression in the T cell compartment of these 113 patients, unbiased clustering was performed. FlowSOM clustering was set to create 25 metaclusters ¹¹⁴(Mcs) and fast interpolation-based t-SNE (Fit-SNE) was used to visualise the proportion of each Mc ¹¹⁵(Figure 2a & b), with a heatmap generated for phenotyping (Figure 2c). As the T-cell panel 116 included markers to define conventional $CD4^+$ and $CD8^+$ subsets, $CD4^{\circ}CD8^{\circ}$ Mcs (7, 8, 11, 14 and

117 22) were excluded and a Partial Least Squares Discriminant Analysis (PLS-DA) was performed to 118 identify the Mcs that contribute to variance between severe and critical infection. Like the PCA ¹¹⁹(Figure 1b) the PLS-DA revealed distinct separation of severe and critical patients, with 43.6% of 120 the variance in the proportion of Mcs accounted for in the first component (Figure 2d). Mc25, 15, 121 and 5 were enriched in critical infection, with Mc23 and 2 enriched in severe infection patients ¹²²(Figure 2e & b). To confirm that the difference in these Mcs were not an artefact of the ¹²³unsupervised nature of the PLS-DA, unpaired Mann-Whitney U-tests comparing the proportions of 124 each Mc between severe and critical patients was performed. Mc25 (GZMB⁺PFN⁺ CD4⁺ CD45RO⁻, 125 $CCR7$, Mc15 (GZMB⁺PFN⁺ CD4⁺ CD45RO⁺, CCR7), and Mc5 (HLA-DR⁺ CD4⁺ CD45RO⁺, 126 $CCR7⁺$) were significantly enriched in critical compared to severe infection (Figure 2f). While the 127 expression of CCR7 and CD45RO on Mc25 and 15 suggest a T_{EMRA} and T_{EM} phenotype 128 respectively, these Mcs also appeared to express intermediate levels of CXCR5 on the heatmap, a 129 feature of CD4⁺ T_{FH} cells (Figure 2c). However, Mcs 25 and 15 displayed a spectrum of expression 130 of CXCR5 (Figure s2) and thus this analysis did not allow definitive determination of T_{FH} 131 phenotype. Therefore, Mc25 and 15 represent cytotoxic $CD4^+$ T lymphocyte subsets, with Mc5 132 being a population of activated T_{CM} cells. The proportion of Mc23 (CD8⁺ CD45RO, CCR7⁺) and 133 Mc2 (CD4⁺ CD45RO, CCR7⁺) were significantly greater in severe patients than critical, 134 representing non-activated naïve (T_N) CD8⁺ and CD4⁺ T cells, respectively (Figure 2f). This 135 analysis suggests an expansion of activated and cytotoxic $CD4^+T$ cells populations and a decrease 136 in the proportion of T_N cell subsets is involved in progression from severe to critical SARS-CoV-2 137 infection.

Cytotoxic CD4⁺ T lymphocytes are characteristic of disease progression

¹⁴⁰As the proportions of naïve and memory T cells were negatively correlated (Figure 1c), the 141 distribution of naïve/memory subsets were further explored in the $CD4^+$ non-T_{FH} and $CD8^+$ T cell 142 compartments by manual gating on CD45RO and CCR7 (Figure 3a). Critical patients exhibited

143 increased proportions of $CD8^+$ T_{EMRA} cells and a reduction in the proportion of $CD4^+$ T_N cells, 144 compared to both mild and severe disease (Figure 3b). In contrast, the T cell compartments in 145 asymptomatic, mild, moderate, and severe patients were composed of comparable proportions of T_N 146 $CD4^+$ and $CD8^+$ cells. While the proportion of $CD4^+$ T_{EMRA} cells was not significantly elevated, 147 critical patients had increased expression of the activation marker HLA-DR on $CD4^+$ T_{EMRA} cells 148 compared to those with asymptomatic or mild disease (Figure 3c). There was also a notable increase 149 in the proportion of $CD8^+$ T_{EMRA} cells expressing the activation marker PD-1 as disease severity 150 worsened (Figure 3c). As Mc25 and 15 could not clearly be defined as T_{FH} cell populations, 151 manually gated CXCR5^{hi} CD4⁺ T_{FH} cells were selected for further analysis. While the proportion of 152 total T_{FH} and CCR7⁺PD-1⁻ T_{FH} cells was not significantly different between groups, the proportion 153 of circulating PD-1⁺CCR7 T_{FH} cells (cT_{FH}) was elevated in critical infection (Figure 3d).

154
1

¹⁵⁵The computational analyses in Figures 1 and 2 revealed distinct populations of cytotoxic 156 (GZMB⁺PFN⁺) CD4⁺ T cell subsets enriched in critical disease. As cytotoxic CD8⁺ T cells have 157 been correlated with disease severity and mortality in COVID-19,²² the proportion of GZMB⁺PFN⁺ $CD4^+$ and $CD8^+$ subsets were of interest to investigate further. As a proportion of lymphocytes, 159 critical patients had expanded populations of cytotoxic $CD4^+$, but not $CD8^+$ T cells. Cytotoxic $CD4^+$ ¹⁶⁰T cells made up a mean of 3.68% of the lymphocyte compartment in critical infection patients, and 161 between 0.41-1.28% in all other disease states (Figure 4a). To delineate the subsets of cytotoxic 162 CD4⁺ T cells contributing to this, the proportions of GZMB⁺PFN⁺ T_{FH} and CD4⁺ non-T_{FH} cells were 163 compared across disease states. Both these subsets were significantly elevated in critical disease, 164 and as such the phenotype of subpopulations within these subsets were explored further (Figure 4b). 165 Of the CD4⁺ non-T_{FH} cell compartment, there was a higher proportion of CD4⁺ T_{EMRA} cells 166 expressing GZMB⁺PFN⁺ cells in critical infection (Figure 4c). This was in line with the 167 predominant T_{EM} and T_{EMRA} phenotype of cytotoxic compared to total CD4⁺ non-T_{FH} cells, which 168 were largely of a T_N and T_{CM} phenotype (Figure 4d). Similarly, cytotoxic CD4⁺ T_{FH} cells were

- 169 almost exclusively of a CCR7PD-1⁺ cT_{FH} phenotype and total T_{FH} cells were predominantly of a
- 170 CCR7⁺PD-1⁻ phenotype (Figure 4e). Finally, the proportion of cytotoxic CD4⁺ and CD8⁺ T cells
- 171 was correlated to determine whether $CD4^+$ cytotoxicity may be a compensating for $CD8^+$ T cell
- 172 exhaustion. However, these two populations correlated positively with each other ($p = 0.0039$:
- 173 Figure 4f). From these data it appears that the expansion of cytotoxic $CD4^+$ cT_{FH} and T_{EMRA}
- 174 populations during SARS-CoV-2 infection is unique to critical disease.

¹⁷⁶**Discussion**

177 Characterising immune responses that associate with different disease severities of COVID-19 may 178 help to define protective immune responses to SARS-CoV-2 and guide the rational development of 179 next-generation vaccines. This study provides a phenotypic analysis of the T cell response in 180 patients experiencing asymptomatic to critical SARS-CoV-2 infection. We confirm that the T cell 181 compartment is distinctly altered in critical SARS-CoV-2 infection, defined by an expansion of ¹⁸²effector memory subsets, and increased expression of activation and cytotoxic functional markers 183 on CD4⁺ T cells. These data suggest a potentially pathogenic role of cytotoxic CD4⁺ CTLs in the 184 progression of COVID-19.

185

 186 CD4⁺ T cells are well-established critical responders in viral infection; however, CTL function is 187 more commonly associated with $CD8⁺$ T cell populations. As such, it is of interest that the top Mcs 188 associated with the progression of disease from severe to critical were activated and cytotoxic $CD4^+$ 189 T cell populations (Figure 2). $CD4^+$ T cells can mediate host-cell death through secretion of 190 granzyme B and perforin^{24,25}, and CD4⁺ CTLs have been identified during viral infections including 191 human immunodeficiency virus (HIV), human cytomegalovirus (CMV), Epstein Barr virus (EBV), 192 influenza, dengue virus and more recently SARS-CoV-2.²⁶ In patients with COVID-19, CD4⁺ T 193 cells expressing high levels of *PFN1*, *GZMB* and *GZMH* transcripts have been identified previously 194 by scRNA-seq to be enriched in hospitalised compared to non-hospitalised COVID-19 patients.²⁷ The data provided in this current study describes an increase in $CD4^+$ CTLs, and a unique 196 expansion of GZMB⁺PFN⁺ CD4 T_{EMRA} cells during critical infection at the level of protein 197 expression. While the circulating T cell populations have been analysed in this cohort, high 198 infiltration of $CD4^+$ CTLs, as well as $CD8^+$ CTLs, have also been reported in the lung parenchyma 199 of severely ill COVID-19 patients.^{24,28} The elevated expression of HLA-II in the respiratory 200 epithelium provides a potential mechanistic basis for the role of $CD4^+$ CTLs in the profound host 201 tissue damage associated with SARS-CoV-2 acute respiratory distress syndrome $(ARDS)^{24}$

203 In the CD4 T_{FH} cell compartment, critical patients also exhibited increased proportions of cytotoxic 204 cells, which were predominantly of a $CCR7PD-1^+$ phenotype; such cells have been previously 205 described as circulating T_{FH} (c T_{FH}) cells.²⁹ Cytotoxic T_{FH} cells have been shown to induce B cell 206 death and to correlate negatively with antibody titres in recurrent Strep A infection in children.³⁰ 207 Post-mortem investigations have shown loss of germinal centre (GC) B cells and absence of GCs in 208 the lymph nodes of COVID-19 decedents. ³¹ However, while cytotoxic cT_{FH} cells were elevated and 209 correlated negatively to anti-S1/S2 SARS-CoV-2 antibodies in hospitalised patients, this correlation 210 was not seen in non-hospitalised patients.²⁷ Conversely, antibody-secreting plasmablasts have been 211 correlated with mortality in COVID-19,²² and higher antibody responses are associated with more 212 severe disease.³² As there are limited studies investigating cytotoxic cT_{FH} in COVID-19, the 213 implications of cytotoxicity in cT_{FH} cells require further investigation to assess any potential 214 detrimental effect this cell type may have on antibody responses to SARS-CoV-2.

 216 CD4⁺ T cell cytotoxicity has been proposed to be a compensatory mechanism to combat exhaustion 217 of $CD8⁺$ T cells, in which $CD8⁺$ CTL expression of GZMB and PFN decrease, and PD-1 218 increases.^{33,34} In contrast, no change in the proportion of $CD8^+$ GZMB⁺PFN⁺ subsets was observed 219 here across disease severities. Moreover, PD-1 expression was not highlighted as a key variable in 220 the separation of disease states in the PCA. This suggests that if $CDS⁺ CTL$ exhaustion was present 221 it was not a differentiating feature of disease progression. As such, the increased proportion of PD-222 $1⁺CD8⁺ T_{EMRA} cells in critical infection likely represents a phenotype of increased activation, rather$ 223 than functional exhaustion. In line with this view, previous studies have reported elevated 224 frequencies of hyperactivated CDS^+ cells, defined by expression of HLA-DR+CD38+PD-1+TIM-3⁺, 225 in severe and critical SARS-CoV-2 infection.^{21,22} While no difference in cytotoxicity was reported 226 here, GZMB and PFN expression has been correlated with critical disease and mortality in COVID-227 19.^{22,35–39} Rha et al., (2021) reported GZMB and PFN were expressed by almost all SARS-CoV-2-

228 specific multimer⁺ CD8⁺ T cells.⁴⁰ As such, enrichment for SARS-CoV-2 specific T cells may 229 provide more insight into the changes in proportion and phenotype of cytotoxic $CD8⁺$ T cells 230 between disease states. In combination with these studies, the data presented here suggest that 231 hyperactivated effector memory subsets of $CD8⁺$ T cells may contribute to COVID-19 progression.

232

233 Investigating the immune response in asymptomatic and mild disease can shed light on the immune 234 response that effectively controls viral replication and disease progression. Control of viral load by 235 T cells was demonstrated in B-cell depleted Rhesus Macaques⁴¹, and $CD8⁺$ T cell responses 236 correlated with better clinical outcome in patients with inborn errors in humoral immune responses 237 and B cell impairment in SARS-CoV-2 infection.^{42,43} In the current study, asymptomatic and mild 238 patients exhibited low frequencies of activated or cytotoxic cells, and a predominantly naïve 239 phenotype in both the $CD4^+$ and $CD8^+$ compartments. However, there is an inherent limitation to 240 investigating the peripheral immune response in a respiratory infection where localised 241 inflammation and resident immune cell responses may not be reflected in circulation.⁴⁴ 242 Furthermore, this study did not investigate SARS-CoV-2-specific T cells, and as such a 243 proportionally smaller T cell response may be missed in these less severe disease states. It has been 244 shown previously that individuals with mild infection are less likely to have detectable SARS-CoV-245 2-specific T cell responses.⁴⁵ In combination with the relative lack of a robust T cell response in 246 asymptomatic and mild disease here, this may question the necessity of a strong T cell response to 247 prevent the progression of COVID-19. This is consistent with the diverse polyclonal, less 248 differentiated SARS-CoV-2 specific T cell response observed in children with mild and 249 asymptomatic T cell response than the clonally expanded memory T cell response with markers of 250 cytotoxicity and exhaustion present in adults.⁴⁶ The protective capacity of T cells should be 251 investigated further to assess whether preserved T cell response against variant SARS-CoV-2 252 viruses provide protection against severe disease, as has been suggested previously. 12,13,16

254 Finally, there are several clinical variables that may confound this analysis, notably the impact of ²⁵⁵age on the immune response to infection. The critical patients were older than asymptomatic and 256 mild patients which is reflective of the high median age of COVID-19 patients admitted to hospital 257 and ICU.⁴⁷ Age over 65 years is associated with a progressive decline in immune function 258 characterised by decreased thymic function, contraction of naive T cell populations, and perturbed 259 T cell function, such as reduced cytokine production and proliferative capacity.^{48,49} It has been 260 shown previously that SARS-CoV-2 immune dysregulation mimics that seen in age-related 261 immunosenescence.⁵⁰ Without age-matched patients, the impact of age cannot be extricated from 262 that of disease severity on the T cell response to SARS-CoV-2.

263

²⁶⁴The data presented in our study add to our understanding of the contribution of T cell responses to 265 disease progression in SARS-CoV-2 infection. The distinct absence of a notable T cell response in 266 asymptomatic disease but expansion of cytotoxic $CD4^+$ CT_{FH} and T_{EMRA} subset in critical disease, 267 suggest that CTLs may be contributing to host tissue damage and systemic inflammatory disease. 268 As such, the potentially detrimental role of T cell responses in COVID-19 should be considered in 269 the development of next-generation therapies and vaccines against SARS-CoV-2.

²⁷⁰**Material and Methods**

²⁷¹**Patient Demographics**

272 SARS-CoV-2 PCR-positive patients and their household contacts were enrolled through the Royal 273 Prince Alfred (RPA) hospital COVID-19 clinic or virtual care system in March of 2020 (COVIMM 274 cohort). Ethics approval was granted by the RPA ethics committee, human ethics number X20-0117 275 and 2020/ETH00770. Verbal consent was given by all participants. Additional patients enrolled in 276 the COSIN study in June 2021 through seven hospital microbiology labs, and out-patient care units 277 across Sydney, Australia, as described by Balachandran et al. (2022) were also included. Ethics 278 approval was granted by Human Research Ethics Committees of the Northern Sydney Local Health 279 District and the University of New South Wales, NSW Australia (ETH00520), and written consent 280 was obtained from all patients.

281 SARS-CoV-2 infection was defined by a positive nasopharyngeal RT-PCR performed by accredited 282 laboratories within the Sydney Health District. Patients were classified as asymptomatic $(n = 5)$, 283 mild (n = 18), moderate (n = 4), severe (n = 5), or critical (n = 3) (Supplementary Table 1). COVID-284 19 disease severity as defined by the NIH guidelines ²⁸⁵(https://www.covid19treatmentguidelines.nih.gov/overview/clinical-spectrum/). Patients were 286 classified as mild if their symptoms were self-manageable.

²⁸⁷**Immunophenotyping by spectral cytometry**

288 Patient PBMCs were isolated from whole blood by Ficoll-density gradient separation, and 289 cryopreserved in Heat-inactivated FBS with 10% DMSO at -80°c. Cryopreserved PMBC samples 290 were thawed and diluted to a concentration of 1 x $10⁶$ live PMBCs in RMPI supplemented with 291 10% FCS and 100 ug/ml streptomycin and penicillin in a U-bottom 96-well plate. Cells were 292 washed in FACS buffer, dead cells labelled with $LIVE/DEAD^{TM}$ Fixable Blue dye (Invitrogen) for 293 20 minutes at 4° C and washed twice in FACS buffer. Cells were stained with extracellular markers ²⁹⁴(Supplementary Table 2; CD3-BUV395 (1:20), CD4-PerCPCy5.5 (1:100), CD8-BUV496 (1:100),

²⁹⁵CD19-BV510 (1:50), CD56-BV605 (1:50), HLA-DR-BV650 (1:50), CD45RO-BV786 (1:50), 296 CD197-PECy7 (1:20), and CXCR5-AF647 (1:20) in FACS buffer for 20 minutes at 4° C. Cells were 297 then permeabilised and fixed with Transcription Factor Buffer Set (BD PharmingenTM) for 40 298 minutes at 4° C. Cells were washed then stained with intracellular markers (Supplementary Table 2) 299 PD-1-BV737 (1:50), Ki-67-BV711 (1:50), Perforin-PE (1:50), and Granzyme B-APC (1:20) in 300 Transcription Factor wash buffer (BD PharmingenTM). Anti-Mouse Ig, κ/Negative Control Particles 301 Set (BDTM CompBeads) were used for single stain controls and stained with corresponding 302 extracellular and intracellular stains. Fluorescent minus one (FMO) controls were included for 303 intracellular markers and stained at the concentration of patient samples at corresponding staining 304 times. The samples underwent a second fixation step with 4% paraformaldehyde for 30 minutes, 305 washed, and resuspended in 200 ml FACS buffer for acquisition. Patient samples and controls were 306 acquired using the 5-laser Cytek Aurora® Spectral Cytometer. Spectral unmixing was performed 307 using the inbuilt SpectroFlo® software after acquisition of unstained and single-stained controls and 308 before patient sample acquisition.

³⁰⁹**Data Analysis**

310 Data analysis was performed in FlowJo v10.8.1, R v4.2.1, and GraphPad Prism v9. Dead cells, 311 doublets, and debris were excluded in FlowJo v10.8.1 by FSC-A, FSC-H, SCC-A, and 312 LIVE/DEAD dye (Figure S1). NKT and B cells were excluded by $CD3^+CD56^+$ and $CD3^-CD19^+$ 313 phenotype, respectively. Compensation for unmixing errors was performed in FlowJo v10.8.1. 314 Irregularities in staining and acquisition between batches were controlled by matching gates on 315 control samples and applying identical gate lineage and functional marker expression within each 316 staining batch.

317 To control for the differences between staining batches, the Principal Component Analysis (Figure 318 1) was calculated using 38 overlapping $CD3^+$ T cell populations that were manually gated in 319 FlowJo v10.8.1. CD4⁺ and CD8⁺ T cells were first divided into T_N (CCR7⁺CD45RO⁻), T_{CM}

320 (CCR7⁺CD45RO⁺), T_{EM} (CCR7⁻CD45RO⁺), T_{EMRA} (CCR7⁻CD45RO⁻) subsets. The frequency of $CD4^+$ and $CD8^+$ T_N, T_{CM}, T_{EM}, and T_{EMRA} subsets, and the cells expressing HLA-DR, PD-1, 322 GRZMB, PFN, and Ki-67 in the T_{CM} , T_{EM} , and T_{EMRA} subsets were included to assess the ³²³significance of T cell function on disease status (Figure S2). Each population was calculated as a 324 proportion of its respective $CD4^+$ or $CD8^+$ T cell compartment, and these frequencies were used for 925 PCA analysis in R v4.2.1 using the Spectre package.⁵¹

326 For the comparison between severe and critical infection, the R package Spectre was utilised for 327 computational analyses $(<https://www.ncbi.nlm.nih.gov/pubmed/33840138>). $CD3^+$ T cells were$ 328 exported for each patient sample. FlowSOM clustering created 25 metaclusters. Fit-SNE 329 dimensionality reduction⁵² was run on subsampled data of 50,000 cells from severe and critical 330 groups to create a representative plot between disease states and a heatmap plot of cellular marker ³³¹expression on each metacluster was created using the pheatmap function. To identify contributions 332 to differences between severe and critical infection, a partial least squares discriminant analysis (PLS-DA) was done.⁵³ To validate the phenotype of metaclusters, an FCS file of marker expression 334 on each metacluster was created using the write.files function in Spectre. This allowed for clear analysis of marker expression for each metacluster in FlowJo v10.8. After exclusion of CD4 CD8 336 FlowSOM metaclusters, PLS-DA was performed to identify the variability in proportion of 337 metaclusters between severe and critical disease. Validation of the statistical differences in 338 proportion of metaclusters between groups was performed in GraphPrism v9.

339 The difference between groups were analysed by two-sided paired Mann-Whitney U-test, and non-340 parametric Kruskal-Wallis, with comparison of the rank mean of experimental groups by Original ³⁴¹False Discovery Rate (FDR) method of Benjamini and Hochberg. Statistical significance between 342 groups in computational analyses were calculated with a permutation ANOVA, with correction for 343 multiple comparisons by FDR method. Statistical significance was set as $p \le 0.05$.

³⁴⁵**Data availability**

- 346 The datasets generated during and/or analysed during the current study are available from the 347 corresponding author on reasonable request.
-

³⁴⁹**Acknowledgments**

- 350 This work was supported by MRFF COVID-19 Vaccine Candidate Research Grant 2007221
- ³⁵¹(J.A.T., C.C., M.S., A.L.F.). F.M.W. and T.M.A. are supported by the International Society for
- 352 the Advancement of Cytometry (ISAC) Marylou Ingram Scholars program. COSIN cohort was
- 353 supported by Snow Medical Foundation as an investigator-initiated study. We acknowledge the
- 354 support of the University of Sydney Advanced Cytometry Facility. The authors thank the study
- 355 participants for their contribution to this research and the clinical staff who collected the samples.

- 357
-
- 359
-

References

- 1. WHO. WHO Coronavirus (COVID-19) Dashboard. https://covid19.who.int. 2022.
- 2. Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, et al. Neutralizing
- 364 antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2
- infection. Nat Med. 2021; **27**: 1205–1211.
- 3. Cromer D, Steain M, Reynaldi A, Schlub TE, Sasson SC, Kent SJ, et al. Neutralising 367 antibodies predict protection from severe COVID-19. Nat Comms. 2023 In Press.
- 4. Liu C, Ginn HM, Dejnirattisai W, Supasa P, Wang B, Tuekprakhon A, et al. Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum. Cell. 2021; **184**: 370 4220-4236.e13.
- 5. Favresse J, Bayart JL, Mullier F, Elsen M, Eucher C, van Eeckhoudt S, et al. Antibody titres decline 3-month post-vaccination with BNT162b2. Emerg Microbes Infect. 2021; **10**: 1495- 1498.
- 6. Vanshylla K, di Cristanziano V, Kleipass F, Dewald F, Schommers P, Gieselmann L, et al. 375 Kinetics and correlates of the neutralizing antibody response to SARS-CoV-2 infection in humans. Cell Host Microbe. 2021: **29**: 917-929.e4.
- 7. Chia WN, Zhu F, Ong SWX, Young BE, Fong SW, le Bert N, et al. Dynamics of SARS-CoV-
- 2 neutralising antibody responses and duration of immunity: a longitudinal study. Lancet Microbe. 2021; **2**: 240-249
- 8. Pegu A, O'Connell SE, Schmidt SD, O'Dell S, Talana CA, Lai L, et al. Durability of mRNA-
- 1273 vaccine–induced antibodies against SARS-CoV-2 variants. Science (1979). 2021; **373**: 1372-1377.
- 9. Geers D, Shamier MC, Bogers S, den Hartog G, Gommers L, Nieuwkoop NN, et al. SARS-
- CoV-2 variants of concern partially escape humoral but not T-cell responses in COVID-19
- convalescent donors and vaccinees. Sci Immunol. 2021; **6**: 782-787.

- ³⁸⁶10. Jung JH, Rha MS, Sa M, Choi HK, Jeon JH, Seok H, et al. SARS-CoV-2-specific T cell
- 387 memory is sustained in COVID-19 convalescent patients for 10 months with successful ³⁸⁸development of stem cell-like memory T cells. Nat Commun. 2021; **12**.
- 389 11. Lu Z, Laing ED, Pena DaMata J, Pohida K, Tso MS, Samuels EC, et al. Durability of SARS-
- ³⁹⁰CoV-2–Specific T-Cell Responses at 12 Months Postinfection. J Infect Dis. 2021; **224**: 2010–
- 391 9.
- ³⁹²12. Tarke A, Coelho CH, Zhang Z, Dan JM, Yu ED, Methot N, et al. SARS-CoV-2 vaccination 393 induces immunological T cell memory able to cross-recognize variants from Alpha to ³⁹⁴Omicron. Cell. 2022; **185**: 847-859.e11.
- 395 13. Tarke A, Sidney J, Methot N, Yu ED, Zhang Y, Dan JM, et al. Impact of SARS-CoV-2
- 396 variants on the total CD4+ and CD8+ T cell reactivity in infected or vaccinated individuals.
- ³⁹⁷Cell Rep Med. 2021; **2**: 100355.
- ³⁹⁸14. Woldemeskel BA, Garliss CC, Blankson JN. SARS-CoV-2 mRNA vaccines induce broad
- ³⁹⁹CD4+ T cell responses that recognize SARS-CoV-2 variants and HCoV-NL63. Journal of ⁴⁰⁰Clinical Investigation. 2021; **131**: e149335
- 401 15. Boni C, Cavazzini D, Bolchi A, Rossi M, Vecchi A, Tiezzi C, et al. Degenerate CD8 Epitopes
- ⁴⁰²Mapping to Structurally Constrained Regions of the Spike Protein: A T Cell-Based Way-Out ⁴⁰³From the SARS-CoV-2 Variants Storm. Front Immunol. 2021; **12**: 730051.
- 404 16. Nathan A, Rossin EJ, Kaseke C, Park RJ, Khatri A, Koundakjian D, et al. Structure-guided ⁴⁰⁵T cell vaccine design for SARS-CoV-2 variants and sarbecoviruses. Cell. 2021; **184**: 4401- 406 4413.e10.
- 407 17. Kent SJ, Khoury DS, Reynaldi A, Juno JA, Wheatley AK, Stadler E, et al. Disentangling the
- 408 relative importance of T cell responses in COVID-19: leading actors or supporting cast? Nat
- ⁴⁰⁹Rev Immunol. 2022; **28**: 387-397.

- 410 18. Rydyznski Moderbacher C, Ramirez SI, Dan JM, Grifoni A, Hastie KM, Weiskopf D, et al.
- 411 Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations
- ⁴¹²with Age and Disease Severity. Cell. 2020; **183**: 996-1012.e19.
- 413 19. Neidleman J, Luo X, George AF, McGregor M, Yang J, Yun C, et al. Distinctive features of
- 414 SARS-CoV-2-specific T cells predict recovery from severe COVID-19. Cell Rep. 2021; 36:
- 415 109414.
- ⁴¹⁶20. Kundu R, Narean JS, Wang L, Fenn J, Pillay T, Fernandez ND, et al. Cross-reactive memory
- 417 T cells associate with protection against SARS-CoV-2 infection in COVID-19 contacts. Nat ⁴¹⁸Commun. 2022; **13**: 80.
- ⁴¹⁹21. Laing AG, Lorenc A, del Molino del Barrio I, Das A, Fish M, Monin L, et al. A dynamic
- ⁴²⁰COVID-19 immune signature includes associations with poor prognosis. Nat Med. 2020; **26**: 421 1623-35.
- ⁴²²22. Kuchroo M, Huang J, Wong P, Grenier JC, Shung D, Tong A, et al. Multiscale PHATE ⁴²³identifies multimodal signatures of COVID-19. Nat Biotechnol. 2022; **40**: 681-691.
- ⁴²⁴23. Bergantini L, d'Alessandro M, Cameli P, Cavallaro D, Gangi S, Cekorja B, et al. NK and T
- ⁴²⁵Cell Immunological Signatures in Hospitalized Patients with COVID-19. Cells. 2021; **10**: 426 3182.
- ⁴²⁷24. Kaneko N, Boucau J, Kuo HH, Perugino C, Mahajan VS, Farmer JR, et al. Temporal changes 428 in T cell subsets and expansion of cytotoxic CD4+ T cells in the lungs in severe COVID-19.
- ⁴²⁹Clinical Immunology. 2022; **237**: 108991.
- ⁴³⁰25. Shenoy AT, Lyon De Ana C, Arafa EI, Salwig I, Barker KA, Korkmaz FT, et al. Antigen 431 presentation by lung epithelial cells directs CD4+ TRM cell function and regulates barrier ⁴³²immunity. Nat Commun. 2021; **12**: 5834.
- ⁴³³26. Juno JA, van Bockel D, Kent SJ, Kelleher AD, Zaunders JJ, Munier CML. Cytotoxic CD4 T ⁴³⁴Cells—Friend or Foe during Viral Infection? Front Immunol. 2017; **8**: 19.

- 27. Meckiff BJ, Ramírez-Suástegui C, Fajardo V, Chee SJ, Kusnadi A, Simon H, et al. Imbalance
- 436 of Regulatory and Cytotoxic SARS-CoV-2-Reactive CD4+ T Cells in COVID-19. Cell. 2020;
- **183**: 1340-1353.e16.
- 28. Carsana L, Sonzogni A, Nasr A, Rossi RS, Pellegrinelli A, Zerbi P, et al. Pulmonary post-
- 439 mortem findings in a series of COVID-19 cases from northern Italy: a two-centre descriptive
- study. Lancet Infect Dis. 2020; **20**: 1135–40.
- 29. He J, Tsai LM, Leong YA, Hu X, Ma CS, Chevalier N, et al. Circulating Precursor CCR7loPD-1hi CXCR5+ CD4+ T Cells Indicate Tfh Cell Activity and Promote Antibody Responses upon Antigen Reexposure. Immunity. 2013; **39**: 770–81.
- 30. Dan JM, Havenar-Daughton C, Kendric K, Al-kolla R, Kaushik K, Rosales SL, et al.
- 445 Recurrent group A Streptococcus tonsillitis is an immunosusceptibility disease involving antibody deficiency and aberrant TFH cells. Sci Transl Med. 2019; **11**: 3776.
- 31. Kaneko N, Kuo HH, Boucau J, Farmer JR, Allard-Chamard H, Mahajan VS, et al. Loss of 448 Bcl-6-Expressing T Follicular Helper Cells and Germinal Centers in COVID-19. Cell. 2020;
- **183**: 143-157.e13.
- 32. Sun J, Tang X, Bai R, Liang C, Zeng L, Lin H, et al. The kinetics of viral load and antibodies to SARS-CoV-2. Clinical Microbiology and Infection. 2020; **28**: 1690.e1-1690.e4.
- 33. Diao B, Wang C, Tan Y, Chen X, Liu Y, Ning L, et al. Reduction and Functional Exhaustion
- 453 of T Cells in Patients With Coronavirus Disease 2019 (COVID-19). Front Immunol. 2020; **11**: 827.
- 34. Takeuchi A, Saito T. CD4 CTL, a Cytotoxic Subset of CD4+ T Cells, Their Differentiation and Function. Front Immunol. 2017; **8**: 194.
- 35. Koutsakos M, Rowntree LC, Hensen L, Chua BY, van de Sandt CE, Habel JR, et al. Integrated immune dynamics define correlates of COVID-19 severity and antibody responses.
- Cell Rep Med. 2021; **2**: 100208.

- ⁴⁶⁰36. Georg P, Astaburuaga-García R, Bonaguro L, Brumhard S, Michalick L, Lippert LJ, et al.
- 461 Complement activation induces excessive T cell cytotoxicity in severe COVID-19. Cell. ⁴⁶²2022; **185**: 493-512.e25.
- ⁴⁶³37. Kang CK, Han GC, Kim M, Kim G, Shin HM, Song KH, et al. Aberrant hyperactivation of
- 464 cytotoxic T-cell as a potential determinant of COVID-19 severity. International Journal of
- ⁴⁶⁵Infectious Diseases. 2020; **97**: 313–21.
- 466 38. Jiang Y, Wei X, Guan J, Qin S, Wang Z, Lu H, et al. COVID-19 pneumonia: CD8+ T and NK
- 467 cells are decreased in number but compensatory increased in cytotoxic potential. Clinical ⁴⁶⁸Immunology. 2020; **218**: 108516.
- ⁴⁶⁹39. Chen Q, Yu B, Yang Y, Huang J, Liang Y, Zhou J, et al. Immunological and inflammatory
- 470 profiles during acute and convalescent phases of severe/ critically ill COVID-19 patients. Int
- ⁴⁷¹Immunopharmacol. 2021; **97**: 107685.
- ⁴⁷²40. Rha MS, Jeong HW, Ko JH, Choi SJ, Seo IH, Lee JS, et al. PD-1-Expressing SARS-CoV-2-
- ⁴⁷³Specific CD8+ T Cells Are Not Exhausted, but Functional in Patients with COVID-19. 474 **Immunity.** 2021; **54**: 44-52.e3.
- 475 41. McMahan K, Yu J, Mercado NB, Loos C, Tostanoski LH, Chandrashekar A, et al. Correlates 476 of protection against SARS-CoV-2 in rhesus macaques. Nature. 2021; **590**: 630–634.
- 477 42. Kinoshita H, Durkee-Shock J, Jensen-Wachspress M, Kankate V v., Lang H, Lazarski CA, et
- 478 al. Robust Antibody and T Cell Responses to SARS-CoV-2 in Patients with Antibody 479 **Deficiency. J Clin Immunol. 2021; 41:** 1146–53.
- ⁴⁸⁰43. Bange EM, Han NA, Wileyto P, Kim JY, Gouma S, Robinson J, et al. CD8+ T cells 481 contribute to survival in patients with COVID-19 and hematologic cancer. Nat Med. 2021; ⁴⁸²**27**: 1280–9.
- ⁴⁸³44. Wauters E, van Mol P, Garg AD, Jansen S, van Herck Y, Vanderbeke L, et al. Discriminating ⁴⁸⁴mild from critical COVID-19 by innate and adaptive immune single-cell profiling of ⁴⁸⁵bronchoalveolar lavages. Cell Res. 2021; **31**: 272–90.

- 486 45. Kroemer M, Spehner L, Vettoretti L, Bouard A, Eberst G, Pili Floury S, et al. COVID-19
- 487 patients display distinct SARS-CoV-2 specific T-cell responses according to disease severity.
- ⁴⁸⁸Journal of Infection. 2021; **82**: 282–327.
- ⁴⁸⁹46. Khoo WH, Jackson K, Phetsouphanh C, Zaunders JJ, Alquicira-Hernandez J, Yazar S, et al.
- 490 Tracking the clonal dynamics of SARS-CoV-2-specific T cells in children and adults with
- ⁴⁹¹mild/asymptomatic COVID-19. Clinical Immunology. 2023; **246**: 109209.
- 492 47. Gao Y, Ding M, Dong X, Zhang J, Kursat Azkur A, Azkur D, et al. Risk factors for severe ⁴⁹³and critically ill COVID19 patients: A review. Allergy. 2021; **76**: 428–55.
- ⁴⁹⁴48. Crooke SN, Ovsyannikova IG, Poland GA, Kennedy RB. Immunosenescence and human 495 vaccine immune responses. Immunity & Ageing. 2019; **16**.
- 496 49. Jalali S, Harpur CM, Piers AT, Auladell M, Perriman L, Li S, et al. A high \Box dimensional 497 cytometry atlas of peripheral blood over the human life span. Immunol Cell Biol. 2022; 100: ⁴⁹⁸805–821.
-
- 499 50. Zheng Y, Liu X, Le W, Xie L, Li H, Wen W, et al. A human circulating immune cell 500 landscape in aging and COVID-19. Protein Cell. 2020; **11**: 740-770.
- 501 51. Ashhurst TM, Marsh□Wakefield F, Putri GH, Spiteri AG, Shinko D, Read MN, et al.
- 502 Integration, exploration, and analysis of high \Box dimensional single \Box cell cytometry data using 503 **Spectre. Cytometry Part A. 2022; 101**: 237–53.
- 504 52. Linderman GC, Rachh M, Hoskins JG, Steinerberger S, Kluger Y. Fast interpolation-based t-505 SNE for improved visualization of single-cell RNA-seq data. Nat Methods. 2019; 16: 243– 506 245.
- 507 53. Marsh□Wakefield F, Juillard P, Ashhurst TM, Juillard A, Shinko D, Putri GH, et al. 508 Peripheral B \Box cell dysregulation is associated with relapse after long \Box term quiescence in 509 patients with multiple sclerosis. Immunol Cell Biol. 2022; **100**: 453–467.
- 510

⁵¹²**Figure Legends**

⁵¹³**Figure 1. Variance in the T cell compartment explained by COVID-19 severity**. **A)** Principal 514 component analysis based on the relative abundance of 38 T cell populations in patients with 515 asymptomatic to critical COVID-19 ($n = 35$). Patient disease severity overlay on principal 516 component analysis where non-overlapping disease states represent a difference in the relative 517 abundance of T cell populations between groups. **B**) Variable contribution plot visualising the T cell 518 populations that contribute to the principal components. Arrow direction represents correlation, 519 where opposing direction is negative and adjacent arrows represent positive correlation between 520 variables. Differences between groups determined by FDR.

522 **Figure 2. Unbiased clustering of T cell compartment in severe and critical patients. A)** FIt-523 SNE visualisation of FlowSOM automatic clustering of a subsample of T cells from each severe (n 524 $=$ 5) and critical (n = 3) patient. **B**) FIt-SNE visualisation of alterations in proportion of metaclusters ⁵²⁵making up the T cell compartment between severe and critical disease. **C)** Heatmap plot showing 526 the relative expression of each marker on self-organised map metaclusters. **D**) Partial Least Squares 527 Discriminant Analysis of relative frequencies of 20 non-redundant $CD4^+$ and $CD8^+$ T cell 528 populations defined by automatic clustering. **E**) Christmas tree plot visualising the variables 529 contributing to variance between severe and critical disease as determined by PLS-DA **F)** Non-530 parametric Mann-Whitney U test of proportions of metaclusters between severe and critical 531 infection patients; error lines represent median \pm interquartile range.

532

532 **Figure 3. Differentiation status of CD4⁺ and CD8⁺ T cell compartments. A) Summary bar plots 533** 534 representing frequency of $CD4^+$ and $CD8^+$ T cell naïve and memory subsets between disease states 535 defined as T_N (CCR7⁺CD45RO), T_{CM} (CCR7⁺CD45RO⁺), T_{EM} (CCR7⁻CD45RO⁺), and T_{EMRA} 536 (CCR7⁻CD45RO⁻). **B**) Frequency of CD4⁺ and CD8⁺ T_N and T_{EMRA} subsets **C**) Frequency of CD4⁺ 537 and $CD8^+$ T_{EMRA} cells expressing HLA-DR and PD-1. **D**) Frequency of total T_{FH} cells defined by 538 $CXCR5^{hi}CD4^+$ phenotype, and $CCR7^+PD-1^-$ and $CCR7^+PD-1^+$ cT_{FH} cells. Difference between

539 groups determined by non-parametric Kruskal-Wallis, with comparison of the rank mean of 540 experimental groups by Original FDR method of Benjamini and Hochberg; error bars represent 541 median \pm interquartile range.

Figure 4. Cytotoxic CD4⁺ and CD8⁺ T cells are expanded in critical infection. A) Frequency of 544 GZMB⁺PFN⁺ CD4⁺ and CD8⁺ T cells across disease states. **B**) Frequency of GZMB⁺PFN⁺ non-T_{FH} 545 cells (CXCR5^{-/lo}) and T_{FH} cells (CXCR5^{hi}) as a proportion of all CD4⁺ T cells **C**) Frequency of 546 GZMB⁺PFN⁺ CD4⁺ T_{EMRA} cells as a proportion of parent **D**) Summary bar plot representing the 547 differentiation status of total $CD4^+$ non-T_{FH} cells and cytotoxic (GZMB⁺PFN⁺) $CD4^+$ T cells 548 defined as T_N (CCR7⁺CD45RO⁻), T_{CM} (CCR7⁺CD45RO⁺), T_{EM} (CCR7⁻CD45RO⁺), and T_{EMRA} $SCER7CD45RO$ in critical infection patients $(n = 3)$. **E**) Summary bar plot representing the 550 differentiation status of total $CD4^+$ T_{FH} (CXCR5⁺) cells and cytotoxic (GZMB⁺PFN⁺) CD4⁺ T_{FH} 551 cells by CCR7⁺PD-1⁻ and CCR7PD-1⁺ (cT_{FH}) cell phenotype in critical infection patients (n = 3). **F**) 552 XY plot of correlation between GZMB⁺PFN⁺ CD4⁺ and CD8⁺ T cells as a proportion of total CD4⁺ 553 and CD8 T^+ cells, respectively. Difference between groups determined by non-parametric Kruskal-554 Wallis, with comparison of the rank mean of experimental groups by Original FDR method of 555 Benjamini and Hochberg; error bars represent median \pm interquartile range.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license . medRxiv preprint doi: [https://doi.org/10.1101/2023.02.17.23286059;](https://doi.org/10.1101/2023.02.17.23286059) this version posted February 23, 2023. The copyright holder for this preprint

⁵⁵⁸**Figure 1. Variance in the T cell compartment explained by COVID-19 severity**. **A)** Principal 559 component analysis based on the relative abundance of 38 T cell populations in patients with asymptomatic to critical COVID-19 ($n = 35$). Patient disease severity overlay on principal 560 asymptomatic to critical COVID-19 ($n = 35$). Patient disease severity overlay on principal component analysis where non-overlapping disease states represent a difference in the relative 561 component analysis where non-overlapping disease states represent a difference in the relative
562 abundance of T cell populations between groups. **B**) Variable contribution plot visualising the T cell 562 abundance of T cell populations between groups. **B**) Variable contribution plot visualising the T cell populations that contribute to the principal components. Arrow direction represents correlation, 563 populations that contribute to the principal components. Arrow direction represents correlation,
564 where opposing direction is negative and adiacent arrows represent positive correlation between 564 where opposing direction is negative and adjacent arrows represent positive correlation between
565 variables. Differences between groups determined by FDR. 565 variables. Differences between groups determined by FDR.
566

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license . medRxiv preprint doi: [https://doi.org/10.1101/2023.02.17.23286059;](https://doi.org/10.1101/2023.02.17.23286059) this version posted February 23, 2023. The copyright holder for this preprint

568 **Figure 2. Unbiased clustering of T cell compartment in severe and critical patients. A)** FIt-- 569 SNE visualisation of FlowSOM automatic clustering of a subsample of T cells from each severe (n = 5) and critical (n = 3) patient. **B**) FIt-SNE visualisation of alterations in proportion of metaclusters 570 = 5) and critical ($n = 3$) patient. **B**) FIt-SNE visualisation of alterations in proportion of metaclusters making up the T cell compartment between severe and critical disease. **C**) Heatmap plot showing 571 making up the T cell compartment between severe and critical disease. **C**) Heatmap plot showing the relative expression of each marker on self-organised map metaclusters. **D**) Partial Least Squares 572 the relative expression of each marker on self-organised map metaclusters. **D**) Partial Least Squares
573 Discriminant Analysis of relative proportions of 20 non-redundant CD4⁺ and CD8⁺ T cell 573 Discriminant Analysis of relative proportions of 20 non-redundant $CD4^+$ and $CD8^+$ T cell
574 nopulations defined by automatic clustering E) Christmas tree plot visualising the variables 574 populations defined by automatic clustering. **E**) Christmas tree plot visualising the variables
575 contributing to variance between severe and critical disease as determined by PLS-DA **F**) Non-575 contributing to variance between severe and critical disease as determined by PLS-DA **F)** Non-576 parametric Mann-Whitney U test of proportions of metaclusters between severe and critical infection patients; error lines represent median \pm interquartile range. 577 infection patients; error lines represent median \pm interquartile range.
578 ers
ng
res
ell
les
pn-

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) . **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2023.02.17.23286059;](https://doi.org/10.1101/2023.02.17.23286059) this version posted February 23, 2023. The copyright holder for this preprint

579

Figure 3. Differentiation status of CD4⁺ and CD8⁺ T cell compartments. A) Summary bar plots representing frequency of CD4⁺ and CD8⁺ T cell naïve and memory subsets between disease states 581 representing frequency of $CD4^+$ and $CD8^+$ T cell naïve and memory subsets between disease states defined as T_N (CCR7⁺CD45RO⁻), T_{CM} (CCR7⁺CD45RO⁺), T_{EM} (CCR7⁻CD45RO⁺), and T_{EMRA} 582 defined as T_N (CCR7⁺CD45RO), T_{CM} (CCR7⁺CD45RO⁺), T_{EM} (CCR7⁻CD45RO⁺), and T_{EMRA}
583 (CCR7⁻CD45RO) **B**) Frequency of CD4⁺ and CD8⁺ T_N and Trape subsets C) Frequency of CD4⁺ (CCR7⁻CD45RO⁻). **B**) Frequency of CD4⁺ and CD8⁺ T_N and T_{EMRA} subsets **C**) Frequency of CD4⁺
584 and CD8⁺ T_{EMBA} cells expressing HI A-DR and PD-1. **D**) Frequency of total T_{EM} cells defined by 584 and $CD8^+$ T_{EMRA} cells expressing HLA-DR and PD-1**. D**) Frequency of total T_{FH} cells defined by
585 CXCR5^{hi}CD4⁺ phenotype, and CCR7⁺PD-1⁻ and CCR7⁻PD-1⁺ cT_{FH} cells. Difference between 585 $CXCR5^{\text{hi}}CD4^+$ phenotype, and $CCR7^+PD-1^-$ and $CCR7^+PD-1^+$ cT_{FH} cells. Difference between 586 groups determined by non-parametric Kruskal-Wallis, with comparison of the rank mean of experimental groups by Original FDR method of Benjamini and Hochberg; error bars represent 587 experimental groups by Original FDR method of Benjamini and Hochberg; error bars represent median \pm interquartile range. median \pm interquartile range.

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) . **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2023.02.17.23286059;](https://doi.org/10.1101/2023.02.17.23286059) this version posted February 23, 2023. The copyright holder for this preprint

Figure 4. Cytotoxic CD4⁺ and CD8⁺ T cells are expanded in critical infection. A) Frequency of G7MB⁺PEN⁺ non-T_{EV} (STMB⁺PEN⁺ non-T_{EV} GZMB⁺PFN⁺ CD4⁺ and CD8⁺ T cells across disease states. B) Frequency of GZMB⁺ 592 GZMB⁺PFN⁺ CD4⁺ and CD8⁺ T cells across disease states. B) Frequency of GZMB⁺PFN⁺ non-T_{FH}
593 cells (CXCR5^{-/lo}) and Tru cells (CXCR5^{hi}) as a proportion of all CD4⁺ T cells C) Frequency of cells (CXCR5^{-/lo}) and T_{FH} cells (CXCR5^{hi}) as a proportion of all CD4⁺ T cells C) Frequency of 594 GZMR⁺PFN⁺ CD4⁺ T_{EMR}, cells as a proportion of parent D) Summary bar plot representing the $GZMB^+PFN^+CD4^+T_{EMRA}$ cells as a proportion of parent D) Summary bar plot representing the
595 differentiation status of total $CD4^+$ non-True cells and eviologic (GZMB⁺PFN⁺) $CD4^+$ T cells 6. 595 differentiation status of total $CD4^+$ non- T_{FH} cells and cytotoxic (GZMB⁺PFN⁺) $CD4^+$ T cells
596 defined as T_N (CCR7⁺CD45RO) T_{CM} (CCR7⁺CD45RO⁺) T_{TM} (CCR7^{-CD45RO</sub>+) and T_{EMBA}} 596 defined as T_N (CCR7⁺CD45RO), T_{CM} (CCR7⁺CD45RO⁺), T_{EM} (CCR7⁻CD45RO⁺), and T_{EMRA}
597 (CCR7⁻CD45RO) in critical infection patients (n = 3), E) Summary bar plot representing the 597 (CCR7⁻CD45RO⁻) in critical infection patients (n = 3). E) Summary bar plot representing the
598 differentiation status of total CD4⁺ T_{EM} (CXCR5⁺) cells and cytotoxic (GZMR⁺PEN⁺) CD4⁺ T_{EM} 598 differentiation status of total CD4⁺ $T_{FH} (CXCR5^+)$ cells and cytotoxic (GZMB⁺PFN⁺) CD4⁺ T_{FH}
599 cells by CCR7⁺PD-1⁻ and CCR7⁻PD-1⁺ (cT_{ry}) cell phenotype in critical infection patients (n = 3) F) s quality cells by CCR7⁺PD-1⁻ and CCR7⁻PD-1⁺ (cT_{FH}) cell phenotype in critical infection patients (n = 3). F)
600 Pearson correlation between GZMR⁺PFN⁺ CD4⁺ and CD8⁺ T cells as a proportion of total CD4 600 Pearson correlation between $GZMB^+PFN^+CD4^+$ and $CD8^+$ T cells as a proportion of total $CD4^+$
601 and CD8 T⁺ cells respectively. Difference between groups determined by non-parametric Kruskal-601 and CD8 T^+ cells, respectively. Difference between groups determined by non-parametric Kruskal-
602 Wallis, with comparison of the rank mean of experimental groups by Original FDR method of 602 Wallis, with comparison of the rank mean of experimental groups by Original FDR method of Benjamini and Hochberg; error bars represent median \pm interguartile range. 603 Benjamini and Hochberg; error bars represent median \pm interquartile range.
604

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) . **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2023.02.17.23286059;](https://doi.org/10.1101/2023.02.17.23286059) this version posted February 23, 2023. The copyright holder for this preprint

⁶⁰⁶**Supplementary Figure 1. Gating strategy for T cells subsets.** Human peripheral blood 607 mononuclear cells (PBMCs) were analysed by spectral cytometry. **A**) Dead cells, cell aggregates, and myeloid cells were excluded by LIVE/DEAD, time, FSC-H, FSC-A, and SSC-A. T cells were 608 and myeloid cells were excluded by LIVE/DEAD, time, FSC-H, FSC-A, and SSC-A. T cells were
609 isolated by CD3⁺CD19 and CD3⁺CD56 phenotype to exclude B cells and NKT cells, respectively. 609 isolated by CD3⁺CD19⁻ and CD3⁺CD56⁻ phenotype to exclude B cells and NKT cells, respectively.
610 **B)** T cells, were divided into CD4⁺ and CD8⁺ T cells. CD4⁺ T cells, were divided further into **B)** T cells were divided into $CD4^+$ and $CD8^+$ T cells. $CD4^+$ T cells were divided further into $C X CR 5^{10}$ $CD4^+$ non-T_{EV} cells and $C X CR 5^{10}$ T_{E} cells. T_{EV} cells were defined as $C F_X$ by $C R 7$ G11 CXCR5^{-/lo} CD4⁺ non-T_{FH} cells and CXCR5^{hi} T_{FH} cells. T_{FH} cells were defined as cT_{FH} by CCR7
612 PD-1⁺ and as CCR7⁺PD-1⁻ cells. CD4⁺ non-T_{FH} and CD8⁺ T cells were divided into naïve/memory
613 613 subsets defined as T_N (CCR7⁺CD45RO⁻), T_{CM} (CCR7⁺CD45RO⁺), T_{EM} (CCR7⁻CD45RO⁺), and
614 T_{EMBA} (CCR7⁻CD45RO⁻). Flow plots of representative non-infected control sample COVIMM 093 T_{EMRA} (CCR7 CD45RO). Flow plots of representative non-infected control sample COVIMM_093
615 and performed in Flow Io v10.8.1 615 and performed in FlowJo v10.8.1.
616

medRxiv preprint doi: [https://doi.org/10.1101/2023.02.17.23286059;](https://doi.org/10.1101/2023.02.17.23286059) this version posted February 23, 2023. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has grante

⁶¹⁹**Supplementary Figure 2. Expression of lineage and functional markers on FIt-SNE of** 620 **metaclusters.** Relative expression of cellular marker expression on FIt-SNE visualisation of 621 FlowSOM automatic clustering of a subsample of T cells from each severe $(n = 5)$ and critical $(n = 5)$ 621 FlowSOM automatic clustering of a subsample of T cells from each severe (n = 5) and critical (n = 622 3) patient. 3) patient. 623

624 Supplementary Table 1. Patient clinical characteristics

626 Supplementary Table 2. Antibody Panel

627 ^TMarkers used for automatic clustering; [‡] Intracellular markers